ubamatamab

{
  "id": "MLC-T-ONC-017383",
  "term": "ubamatamab",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific, human monoclonal antibody with potential antineoplastic activity. REGN4018 contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen that is part of the T-cell receptor complex, and one for human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a member of the mucin family of glycoproteins that is overexpressed by several epithelial cancers, including ovarian cancer. Upon administration, ubamatamab binds to both T cells and MUC16-expressing tumor cells, which cross-links the T cells to the tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells.",
  "synonyms": [
    "MUC16xCD3 bispecific T-cell engager REGN4018",
    "bispecific T-cell engager antibody REGN4018",
    "MUC16/CD3-directed bispecific T-cell engager antibody REGN4018",
    "anti-MUC16 x anti-CD3 REGN4018",
    "anti-MUC16/CD3 bispecific antibody REGN4018"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ubamatamab/"
}